1. Scrip

Pfizer's CEO Is Bullish On Rebate Changes That Could Power New Launches

 
• By Jessica Merrill

Ian Read walked away from a meeting with President Trump with a rosy view on drug pricing and rebate reform. He said he expects rebates will be eliminated, but net drug prices will continue to grow. Rebate reform will benefit new drug launches, he predicted.

Rebates_535538281_1200.jpg

After both a phone call and a White House meeting with President Donald Trump, Pfizer Inc. CEO Ian Read was pushed during the firm’s second quarter earnings call for his thoughts on what could be on the horizon when it comes to drug pricing and rebate reform – and the CEO was notably optimistic about US policy changes that could impact the pharmaceutical industry.

Read said he expects drug rebates will be eliminated under public health insurance plans in a policy shift that will spill over to the private sector. At the same time,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list